CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemia

by Pulte, Dianne, Olson, Kim E, Broekman, M Johan, Islam, Naziba, Ballard, Harold S, Furman, Richard R, Olson, Ashley E, Marcus, Aaron J
Published 2007

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

by de Vos, Sven, Forero-Torres, Andres, Ansell, Stephen M, Kahl, Brad, Cheson, Bruce D, Bartlett, Nancy L, Furman, Richard R, Winter, Jane N, Kaplan, Henry, Timmerman, John, Whiting, Nancy C, Drachman, Jonathan G, Advani, Ranjana
Published 2014

Management of adverse events associated with idelalisib treatment: expert panel opinion

by Coutré, Steven E., Barrientos, Jacqueline C., Brown, Jennifer R., de Vos, Sven, Furman, Richard R., Keating, Michael J., Li, Daniel, O’Brien, Susan M., Pagel, John M., Poleski, Martin H., Sharman, Jeff P., Yao, Nai-Shun, Zelenetz, Andrew D.
Published 2015

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

by Licht, Christoph, Greenbaum, Larry A, Muus, Petra, Babu, Sunil, Bedrosian, Camille L, Cohen, David J, Delmas, Yahsou, Douglas, Kenneth, Furman, Richard R, Gaber, Osama A, Goodship, Timothy, Herthelius, Maria, Hourmant, Maryvonne, Legendre, Christophe M, Remuzzi, Giuseppe, Sheerin, Neil, Trivelli, Antonella, Loirat, Chantal
Published 2015